| Name | Title | Contact Details |
|---|---|---|
Lawrence Miller |
Founder, Chief Executive Officer and Board Chair | Profile |
Ted Harding |
Chief Human Resources Officer | Profile |
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.
Colorcon is a West Point, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BPR-Bechtel is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Septodont is a New Castle, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.